* Hoeg's departure comes amid broader shakeup of health agency
(Correction clarifies that the phase III Volga trial was conducted across three arms and provides the findings for arms 1 and 2 versus the comparator arm)
(Alliance News) - Patients with aggressive stomach cancer are to benefit from a new type of treatment after the NHS spending watchdog approved the first immunotherapy for people with this form of canc...
(Sharecast News) - UK pharma group AstraZeneca on Thursday reported positive results from the Phase III VOLGA trial for its Imfinzi bladder cancer treatment.
(Alliance News) - AstraZeneca PLC on Thursday posted positive trial results for its bladder cancer treatment imfinzi.
Date:
13-May-26
Broker:
Jefferies
Recommendation:
Buy
Old Target:
18,000.00
New Target:
18,000.00
Rating Type:
Reiteration
(Alliance News) - AstraZeneca on Tuesday hailed encouraging test results for its hypoparathyroidism drug eneboparatide.
* Novo nudges up full-year guidance after sales, profit beats
Date:
06-May-26
Broker:
Deutsche
Recommendation:
Sell
Old Target:
11,500.00
New Target:
11,500.00
Rating Type:
Reiteration
(Alliance News) - The following London-listed shares received analyst recommendations on Tuesday morning and on Monday:
May 1 (Reuters) - London's blue-chip FTSE 100 closed slightly lower on Friday, dragged down by losses in heavyweight energy stocks and drugmaker AstraZeneca, while a looming UK public holiday thinn...
(Alliance News) - The FTSE 100 closed down on Friday, but above early lows, while the oil price fell amid reports that Iran has made a new proposal amid stalled US peace talks.
(Sharecast News) - London stocks ended mixed on Friday as investors weighed ongoing concerns about the Strait of Hormuz blockade against resilient domestic data, after the Bank of England warned that...
* FDA panel votes against camizestrant over trial design concerns
(Alliance News) - AstraZeneca PLC on Friday said it had secured a recommendation for its cancer drug Truqap from US authorities, but failed to secure a majority in favour of its treatment camizestrant...
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Says the US Food & Drug Administration's Oncologic Drugs Advisory Committee recommended the benefit–risk profile of Truqap when used w...
* Defense stocks lead gains, aided by Rolls-Royce
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:
* Earnings mixed. Healthcare stocks drag, Adidas outperforming
(Alliance News) - The FTSE 100 closed lower on Wednesday, held back by falls in drugs firms GSK and AstraZeneca, while oil surged amid reports that the US is eyeing a longer blockade of the Strait of...
* Stock top decliner on the FTSE 100
* Q1 oncology sales up 16%, rare disease sales up 15%
* Investment follows US-UK deal aimed at increased drug prices
(Alliance News) - Cambridge, England-based pharmaceutical firm AstraZeneca PLC will pump GBP300 million into UK drugs development in a "major vote of confidence" in the country, the prime minister has...
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.
(Alliance News) - Stock prices in London opened lower on Wednesday, as renewed uncertainty in energy markets and a heavy slate of corporate updates weighed on sentiment ahead of the Fed's rate call.
(Alliance News) - AstraZeneca PLC on Wednesday reported better-than-expected first-quarter revenue and profit, and flagged the potential for its drugs pipeline amid numerous positive trial findings an...
(Alliance News) - AstraZeneca, Lloyds Banking Group and GSK report higher earnings in the first quarter.
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that it had delivered solid revenue growth and a series of positive late‑stage trial readouts in the first quarter, reinforcing confide...
* Program aims to reduce trial delays, cut years off drug approval timelines
Date:
28-Apr-26
Broker:
Deutsche
Recommendation:
Sell
Old Target:
11,500.00
New Target:
11,500.00
Rating Type:
Reiteration
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Breztri Aerosphere is approved by the US Food & Drug Administration as a maintenance treatment for asthma in patients 12 years and old...
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it asthma maintenance treatment Breztri Aerosphere had received approval from the US Food and Drug Administration for adults and adolescen...
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Monday.
(Alliance News) - AstraZeneca PLC on Monday said its self-administered lupus treatment has been approved in the US.
(Alliance News) - GSK reports on a US court ruling in ongoing litigation, AstraZeneca announces US approval for a self-administered lupus treatment, while Harworth Group receives planning consent for...
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its systemic lupus erythematosus treatment Saphnelo (anifrolumab) hsd received US Food and Drug Administration approval for self‑admi...
(Alliance News) - The FTSE 100 ended the week on the back foot as the crisis in the Middle East remained deadlocked.
April 23 (Reuters) - Two veteran U.S. Supreme Court lawyers are leaving law firm Paul Weiss for rival Davis Polk, another challenge for the firm after its longtime chairman Brad Karp in February r...
* Roche, Sanofi plan Europe drug launches despite hurdles
AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Rene Haas will step down as a non-executive director on Thursday next week, the end of April, due to his increased executive duties...